This review provides an overview of important pharmacological, dosing schedule, and clinical properties of cladribine tablets relevant to its use in the treatment of patients with relapsing-remitting multiple sclerosis.
Guiding commentary has been provided by Professor Helmut Butzkueven, an academic neurologist specialising in multiple sclerosis research. He is the Van Cleef Roet Professor of Neuroscience, Monash University and Director of Neurology at Alfred Health (both in Melbourne, Australia). He is also the Managing Director of the MSBase Foundation, a global MS registry which commenced in 2004, and monitors outcomes in over 125,000 patients in 46 countries.
Please login below to download this issue (PDF)